Analysts at Roth Capital increased their price target on shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) from $2.75 to $3.75 in a research report issued to clients and investors on Wednesday, AmericanBankingNews.com reports. Roth Capital’s target price suggests a potential upside of 42.05% from the company’s current price.
Other equities research analysts have also recently issued reports about the stock. Analysts at Maxim Group initiated coverage on shares of Catalyst Pharmaceutical Partners in a research note to investors on Tuesday, September 24th. They set a “buy” rating and a $4.00 price target on the stock. Separately, analysts at Aegis raised their price target on shares of Catalyst Pharmaceutical Partners from $3.50 to $4.00 in a research note to investors on Friday, September 6th. They now have a “buy” rating on the stock. Finally, analysts at Zacks reiterated a “hold” rating on shares of Catalyst Pharmaceutical Partners in a research note to investors on Tuesday, August 27th. They now have a $1.00 price target on the stock.
Shares of Catalyst Pharmaceutical Partners (NASDAQ:CPRX) traded down 2.22% on Wednesday, hitting $2.64. The stock had a trading volume of 859,576 shares. Catalyst Pharmaceutical Partners has a 52-week low of $0.37 and a 52-week high of $3.65. The stock’s 50-day moving average is $2.64 and its 200-day moving average is $1.38. The company’s market cap is $109.5 million.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) last issued its quarterly earnings data on Thursday, August 15th. The company reported ($0.06) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.07) by $0.01. Analysts expect that Catalyst Pharmaceutical Partners will post $-0.24 EPS for the current fiscal year.
Catalyst Pharmaceutical Partners, Inc (NASDAQ:CPRX) is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting diseases of the central nervous system with a focus on the treatment of addiction and epilepsy.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.